Ventyx Biosciences Inc (NASDAQ: VTYX) has experienced a rise in its stock price by 1.83 compared to its previous closing price of 1.91. However, the company has seen a fall of -1.77% in its stock price over the last five trading days. globenewswire.com reported 2024-08-08 that A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024
Is It Worth Investing in Ventyx Biosciences Inc (NASDAQ: VTYX) Right Now?
Company’s 36-month beta value is 0.43.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VTYX is 54.57M, and currently, short sellers hold a 16.50% ratio of that floaft. The average trading volume of VTYX on August 15, 2024 was 1.11M shares.
VTYX’s Market Performance
VTYX’s stock has seen a -1.77% decrease for the week, with a -34.29% drop in the past month and a -53.58% fall in the past quarter. The volatility ratio for the week is 5.73%, and the volatility levels for the past 30 days are at 7.91% for Ventyx Biosciences Inc The simple moving average for the past 20 days is -16.86% for VTYX’s stock, with a -51.70% simple moving average for the past 200 days.
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at -25.90% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.91% of loss for the given period.
Volatility was left at 7.91%, however, over the last 30 days, the volatility rate increased by 5.73%, as shares sank -29.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.87% lower at present.
During the last 5 trading sessions, VTYX fell by -2.27%, which changed the moving average for the period of 200-days by -86.76% in comparison to the 20-day moving average, which settled at $2.2987. In addition, Ventyx Biosciences Inc saw -21.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Krueger Christopher W, who sale 1,651 shares at the price of $5.40 back on Apr 02 ’24. After this action, Krueger Christopher W now owns 284,999 shares of Ventyx Biosciences Inc, valued at $8,921 using the latest closing price.
Nuss John, the CHIEF SCIENTIFIC OFFICER of Ventyx Biosciences Inc, sale 1,651 shares at $5.40 during a trade that took place back on Apr 02 ’24, which means that Nuss John is holding 264,998 shares at $8,921 based on the most recent closing price.
Stock Fundamentals for VTYX
Current profitability levels for the company are sitting at:
- -170.61 for the present operating margin
- -0.29 for the gross margin
The net margin for Ventyx Biosciences Inc stands at -159.2. The total capital return value is set at -0.63. Equity return is now at value -56.29, with -52.07 for asset returns.
Based on Ventyx Biosciences Inc (VTYX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -14.07. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -50.7.
Currently, EBITDA for the company is -204.55 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 100.83. The receivables turnover for the company is 2.15for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.19.
Conclusion
In a nutshell, Ventyx Biosciences Inc (VTYX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
